title: Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial.
abstract: Contrasting data partially support a certain antihypertensive efficacy of lactotripeptides (LTPs) derived from enzymatic treatment of casein hydrolysate. Our aim was to evaluate this effect on a large number of hemodynamic parameters. We conducted a prospective double-blind randomized clinical trial, which included 52 patients affected by high-normal blood pressure (BP) or first-degree hypertension. We investigated the effect of a 6-week treatment with the LTPs isoleucine-proline-proline and valine-proline-proline at 3 mg per day, assumed to be functional food, on office BP, 24-h ambulatory BP monitoring (ABPM) values, stress-induced BP increase and cardiac output-related parameters. In the LTP-treated subjects, we observed a significant reduction in office systolic BP (SBP; -5±8 mm Hg, P=0.013) and a significant improvement in pulse wave velocity (PWV; -0.66±0.81 m s(-1), P=0.001; an instrumental biomarker of vascular rigidity). No effect on 24-h ABPM parameters and BP reaction to stress was observed from treatment with the combined LTPs. LTPs, but not placebo, were associated with a mild but significant change in the stroke volume (SV), SV index (markers of cardiac flow), the acceleration index (ACI) and velocity index (VI) (markers of cardiac contractility). No effect was observed on parameters related to fluid dynamics or vascular resistance. LTPs positively influenced the office SBP, PWV, SV, SV index, ACI and VI in patients with high-normal BP or first-degree hypertension.
authors.affiliation: Hypertension Research Center, Department of Internal Medicine, Aging and Kidney Disease, University of Bologna, Bologna, Italy. afgcicero@cardionet.it
authors.forename: Arrigo F G
authors.initials: AF
authors.lastname: Cicero
authors.forename: Martina
authors.initials: M
authors.lastname: Rosticci
authors.forename: Beatrice
authors.initials: B
authors.lastname: Gerocarni
authors.forename: Stefano
authors.initials: S
authors.lastname: Bacchelli
authors.forename: Maddalena
authors.initials: M
authors.lastname: Veronesi
authors.forename: Enrico
authors.initials: E
authors.lastname: Strocchi
authors.forename: Claudio
authors.initials: C
authors.lastname: Borghi
mesh_terms: D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D002364:Caseins / Q000737:chemistry; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D011673:Pulsatile Flow / Q000187:drug effects / Q000502:physiology; D013312:Stress, Physiological / Q000187:drug effects*
chemical_list: D002364:Caseins; D009842:Oligopeptides; C489032:isoleucyl-prolyl-proline; C489031:valyl-prolyl-proline; C475729:casein hydrolysate